Scarica l'app Stockscreener
146.40
7.42%
10.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$136.30
Aprire:
$136.5
Volume 24 ore:
6.17M
Relative Volume:
1.95
Capitalizzazione di mercato:
$29.02B
Reddito:
$742.00K
Utile/perdita netta:
$-1.13B
Rapporto P/E:
-24.74
EPS:
-5.9165
Flusso di cassa netto:
$-913.73M
1 W Prestazione:
+52.05%
1M Prestazione:
+54.34%
6M Prestazione:
+208.23%
1 anno Prestazione:
+301.45%
Intervallo 1D:
$134.66
$146.70
Intervallo di 1 settimana:
$94.63
$146.70
Portata 52W:
$34.00
$146.70
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
146.44 | 19.11B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
443.66 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.50 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
827.22 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
337.09 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.85 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Investors Purchase High Volume of Revolution Medicines Call Options (NASDAQ:RVMD) - MarketBeat
RVMD Maintains by RBC Capital -- Price Target Raised to $162 - GuruFocus
RVMD Maintained by Wells Fargo -- Price Target Raised to $167 - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Given New $167.00 Price Target at Wells Fargo & Company - MarketBeat
Revolution Medicines Stock Soars on Breakthrough Cancer Data - TipRanks
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $200 - GuruFocus
RVMD Reiterated by Wedbush -- Price Target Maintained at $147.00 - GuruFocus
RVMD Maintained by Guggenheim -- Price Target Raised to $175 - GuruFocus
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report) - FinancialContent
Why Did Oncology Stock Revolution Medicines (RVMD) Gain 41% Monday? - Investorideas.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
RVMD Maintained by HC Wainwright & Co. -- Price Target Raised to $169 - GuruFocus
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright raises Revolution Medicines price target to $169 - Investing.com
Pancreatic cancer pill shown to nearly double overall survival time, drug company says - The Hill
H.C. Wainwright raises Revolution Medicines price target to $169 By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed? - Yahoo Finance
Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136? - TradingKey
Baillie Gifford & Co. Invests $15.53 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
US biotech seeks quick FDA approval after improved survivability with cancer candidate - medwatch.com
Revolution Medicines Stock Surges After Trial Data: Is Biotech Back? - EBC Financial Group
Revolution Medicines (RVMD) Sees Potential Surge Following Phase III Trial Success - GuruFocus
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial - Insider Monkey
Revolution Medicines (RVMD) Plans $1 Billion in Offerings to Bol - GuruFocus
Revolution’s daraxonrasib nails endpoints in pancreatic cancer trial - BioWorld News
Revolution Medicines plans $1 billion dual offering By Investing.com - Investing.com India
RVMD Stock Jumps As Analysts Hike Price Targets On Pancreatic Cancer Bets - timothysykes.com
Revolution Medicines shares pop after pancreatic cancer drug trial win - CNBC
Revolution Medicines shares jump on breakthrough pancreatic cancer trial results - MSN
Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes - TradingView — Track All Markets
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Revolution Medicines (RVMD) files $750M share sale; $250M convertible notes planned - Stock Titan
Revolution Medicines (NASDAQ: RVMD) seeks $250M via convertible notes, concurrent $750M stock sale - Stock Titan
Revolution Medicines plans $1 billion dual offering - Investing.com
Top Biotech Catapults On 'Unprecedented' Results In Cancer - Investor's Business Daily
Revolution Medicines Announces Unprecedented Survival Gains with Daraxonrasib in Late-Stage Pancreatic Cancer Study - BBN Times
U.S. Markets Rose Monday; Revolution Medicines Topped Leaders - Barron's
Leerink Partners Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $147.00 - MarketBeat
Revolution Medicines seeks $1B to fund cancer-drug R&D, launch prep - Stock Titan
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial - MedCity News
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy? - Barchart.com
Revolution Medicines stock hits all-time high at 132.41 USD By Investing.com - Investing.com Australia
RVMD Stock Rallies As Analysts Hike Price Targets On Trial Momentum - timothysykes.com
RVMD Maintained by Oppenheimer -- Price Target Raised to $165 - GuruFocus
Revolution Medicines (RVMD) Stock Surges 38.7% - GuruFocus
Revolution Medicines surges 38% on pancreatic cancer breakthrough - CryptoRank
Revolution Medicines Announces Breakthrough in Pancreatic Cancer Treatment with daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Sees Remarkable 37.9% Surge - GuruFocus
Revolution Medicines: PDAC Data Wows Wall StreetJury's Out On Further Upside (RVMD) - Seeking Alpha
RVMD Stock Jumps As Analysts Hike Targets On Trial Hopes - StocksToTrade
Revolution Medicines reports positive Phase 3 results for daraxonrasib in pancreatic cancer By Investing.com - Investing.com India
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):